{"id":380339,"date":"2020-11-12T16:13:38","date_gmt":"2020-11-12T21:13:38","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=380339"},"modified":"2020-11-12T16:13:38","modified_gmt":"2020-11-12T21:13:38","slug":"important-dec-22-deadline-pawar-law-group-announces-a-securities-class-action-lawsuit-against-innate-pharma-s-a-ipha","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/important-dec-22-deadline-pawar-law-group-announces-a-securities-class-action-lawsuit-against-innate-pharma-s-a-ipha\/","title":{"rendered":"IMPORTANT DEC. 22 DEADLINE Pawar Law Group Announces a Securities Class Action Lawsuit Against Innate Pharma S.A.\u2013 IPHA"},"content":{"rendered":"<div class=\"mw_release\">\n<p>NEW YORK, Nov.  12, 2020  (GLOBE NEWSWIRE) &#8212; Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Innate Pharma S.A. (NASDAQ: IPHA) from March 10, 2020 through September 8, 2020, inclusive (the \u201cClass Period\u201d). The lawsuit seeks to recover damages for Innate Pharma S.A. investors under the federal securities laws.<\/p>\n<p>To join the class action, go <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=tBlKzYGN_BSFP2zsXz55J_FS-y2Yu8WWWNz91ezSjMIg6ocjyaMy26F5WLmm4CdmCDMsok7KMztmy4Vxq0gRtPUR0EnOVXKrTyduTlhI_Ag=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">here<\/a> or call Vik Pawar, Esq. toll-free at 888-589-9804 or email\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ktihe89MXewdDNwZMHnoOVZu1Ixiaqnn_2SG68NSF4jTrfyJRyrLPI_NjxVP-DN4j0pPflyNBcYlCdJ6vJ3CbFcH4R8njMN3JpSB21NXsD0=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">info@pawarlawgroup.com<\/a>\u00a0for information on the class action.<\/p>\n<p>According to the lawsuit, defendants throughout the Class Period made false and\/or misleading statements and\/or failed to disclose that: (1) Innate touted the results of their various Phase 2 trials as being within expectations; (2) Innate continued to reassure investors that they were eligible for the $100 million payment upon first dosing of Phase 3 trials; (3) Innate failed to timely disclose their renegotiations with AstraZeneca to split the $100 million payment into two $50 million payments, to be partially contingent on performance during the Phase 3 trials; and (4) as a result, Defendants\u2019 statements about its business, operations, and prospects, were materially false and misleading and\/or lacked a reasonable basis at all relevant times.<\/p>\n<p>If you wish to serve as lead plaintiff, you must move the Court no later than December 22, 2020. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.<\/p>\n<p>No class has been certified. Until a class is certified, you are not represented by counsel unless you hire one. You may hire counsel of your choice. You may also do nothing at this time and be an absent member of the class. Your ability to share in any future recovery is not dependent upon being a lead plaintiff.<\/p>\n<p>Pawar Law Group represents investors from around the world. Attorney advertising. Prior results do not guarantee or predict a similar outcome with respect to any future matter.<br \/>&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;-<\/p>\n<p>Contact:\u00a0\u00a0<br \/>Vik Pawar, Esq.\u00a0\u00a0<br \/>Pawar Law Group\u00a0\u00a0<br \/>20 Vesey Street, Suite 1410\u00a0\u00a0<br \/>New York, NY 10007\u00a0\u00a0<br \/>Tel: (917) 261-2277\u00a0\u00a0<br \/>Fax: (212) 571-0938\u00a0\u00a0<br \/>info@pawarlawgroup.com<\/p>\n<p \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4NTM0MSMzODI1MjAyIzIwODMxNDk=\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>NEW YORK, Nov. 12, 2020 (GLOBE NEWSWIRE) &#8212; Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Innate Pharma S.A. (NASDAQ: IPHA) from March 10, 2020 through September 8, 2020, inclusive (the \u201cClass Period\u201d). The lawsuit seeks to recover damages for Innate Pharma S.A. investors under the federal securities laws. To join the class action, go here or call Vik Pawar, Esq. toll-free at 888-589-9804 or email\u00a0info@pawarlawgroup.com\u00a0for information on the class action. According to the lawsuit, defendants throughout the Class Period made false and\/or misleading statements and\/or failed to disclose that: (1) Innate touted the results of their various Phase 2 trials as being within expectations; (2) Innate continued &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/important-dec-22-deadline-pawar-law-group-announces-a-securities-class-action-lawsuit-against-innate-pharma-s-a-ipha\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;IMPORTANT DEC. 22 DEADLINE Pawar Law Group Announces a Securities Class Action Lawsuit Against Innate Pharma S.A.\u2013 IPHA&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-380339","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>IMPORTANT DEC. 22 DEADLINE Pawar Law Group Announces a Securities Class Action Lawsuit Against Innate Pharma S.A.\u2013 IPHA - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/important-dec-22-deadline-pawar-law-group-announces-a-securities-class-action-lawsuit-against-innate-pharma-s-a-ipha\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"IMPORTANT DEC. 22 DEADLINE Pawar Law Group Announces a Securities Class Action Lawsuit Against Innate Pharma S.A.\u2013 IPHA - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"NEW YORK, Nov. 12, 2020 (GLOBE NEWSWIRE) &#8212; Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Innate Pharma S.A. (NASDAQ: IPHA) from March 10, 2020 through September 8, 2020, inclusive (the \u201cClass Period\u201d). The lawsuit seeks to recover damages for Innate Pharma S.A. investors under the federal securities laws. To join the class action, go here or call Vik Pawar, Esq. toll-free at 888-589-9804 or email\u00a0info@pawarlawgroup.com\u00a0for information on the class action. According to the lawsuit, defendants throughout the Class Period made false and\/or misleading statements and\/or failed to disclose that: (1) Innate touted the results of their various Phase 2 trials as being within expectations; (2) Innate continued &hellip; Continue reading &quot;IMPORTANT DEC. 22 DEADLINE Pawar Law Group Announces a Securities Class Action Lawsuit Against Innate Pharma S.A.\u2013 IPHA&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/important-dec-22-deadline-pawar-law-group-announces-a-securities-class-action-lawsuit-against-innate-pharma-s-a-ipha\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-11-12T21:13:38+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4NTM0MSMzODI1MjAyIzIwODMxNDk=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/important-dec-22-deadline-pawar-law-group-announces-a-securities-class-action-lawsuit-against-innate-pharma-s-a-ipha\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/important-dec-22-deadline-pawar-law-group-announces-a-securities-class-action-lawsuit-against-innate-pharma-s-a-ipha\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"IMPORTANT DEC. 22 DEADLINE Pawar Law Group Announces a Securities Class Action Lawsuit Against Innate Pharma S.A.\u2013 IPHA\",\"datePublished\":\"2020-11-12T21:13:38+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/important-dec-22-deadline-pawar-law-group-announces-a-securities-class-action-lawsuit-against-innate-pharma-s-a-ipha\\\/\"},\"wordCount\":352,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/important-dec-22-deadline-pawar-law-group-announces-a-securities-class-action-lawsuit-against-innate-pharma-s-a-ipha\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA4NTM0MSMzODI1MjAyIzIwODMxNDk=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/important-dec-22-deadline-pawar-law-group-announces-a-securities-class-action-lawsuit-against-innate-pharma-s-a-ipha\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/important-dec-22-deadline-pawar-law-group-announces-a-securities-class-action-lawsuit-against-innate-pharma-s-a-ipha\\\/\",\"name\":\"IMPORTANT DEC. 22 DEADLINE Pawar Law Group Announces a Securities Class Action Lawsuit Against Innate Pharma S.A.\u2013 IPHA - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/important-dec-22-deadline-pawar-law-group-announces-a-securities-class-action-lawsuit-against-innate-pharma-s-a-ipha\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/important-dec-22-deadline-pawar-law-group-announces-a-securities-class-action-lawsuit-against-innate-pharma-s-a-ipha\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA4NTM0MSMzODI1MjAyIzIwODMxNDk=\",\"datePublished\":\"2020-11-12T21:13:38+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/important-dec-22-deadline-pawar-law-group-announces-a-securities-class-action-lawsuit-against-innate-pharma-s-a-ipha\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/important-dec-22-deadline-pawar-law-group-announces-a-securities-class-action-lawsuit-against-innate-pharma-s-a-ipha\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/important-dec-22-deadline-pawar-law-group-announces-a-securities-class-action-lawsuit-against-innate-pharma-s-a-ipha\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA4NTM0MSMzODI1MjAyIzIwODMxNDk=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA4NTM0MSMzODI1MjAyIzIwODMxNDk=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/important-dec-22-deadline-pawar-law-group-announces-a-securities-class-action-lawsuit-against-innate-pharma-s-a-ipha\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"IMPORTANT DEC. 22 DEADLINE Pawar Law Group Announces a Securities Class Action Lawsuit Against Innate Pharma S.A.\u2013 IPHA\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"IMPORTANT DEC. 22 DEADLINE Pawar Law Group Announces a Securities Class Action Lawsuit Against Innate Pharma S.A.\u2013 IPHA - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/important-dec-22-deadline-pawar-law-group-announces-a-securities-class-action-lawsuit-against-innate-pharma-s-a-ipha\/","og_locale":"en_US","og_type":"article","og_title":"IMPORTANT DEC. 22 DEADLINE Pawar Law Group Announces a Securities Class Action Lawsuit Against Innate Pharma S.A.\u2013 IPHA - Market Newsdesk","og_description":"NEW YORK, Nov. 12, 2020 (GLOBE NEWSWIRE) &#8212; Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Innate Pharma S.A. (NASDAQ: IPHA) from March 10, 2020 through September 8, 2020, inclusive (the \u201cClass Period\u201d). The lawsuit seeks to recover damages for Innate Pharma S.A. investors under the federal securities laws. To join the class action, go here or call Vik Pawar, Esq. toll-free at 888-589-9804 or email\u00a0info@pawarlawgroup.com\u00a0for information on the class action. According to the lawsuit, defendants throughout the Class Period made false and\/or misleading statements and\/or failed to disclose that: (1) Innate touted the results of their various Phase 2 trials as being within expectations; (2) Innate continued &hellip; Continue reading \"IMPORTANT DEC. 22 DEADLINE Pawar Law Group Announces a Securities Class Action Lawsuit Against Innate Pharma S.A.\u2013 IPHA\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/important-dec-22-deadline-pawar-law-group-announces-a-securities-class-action-lawsuit-against-innate-pharma-s-a-ipha\/","og_site_name":"Market Newsdesk","article_published_time":"2020-11-12T21:13:38+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4NTM0MSMzODI1MjAyIzIwODMxNDk=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/important-dec-22-deadline-pawar-law-group-announces-a-securities-class-action-lawsuit-against-innate-pharma-s-a-ipha\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/important-dec-22-deadline-pawar-law-group-announces-a-securities-class-action-lawsuit-against-innate-pharma-s-a-ipha\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"IMPORTANT DEC. 22 DEADLINE Pawar Law Group Announces a Securities Class Action Lawsuit Against Innate Pharma S.A.\u2013 IPHA","datePublished":"2020-11-12T21:13:38+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/important-dec-22-deadline-pawar-law-group-announces-a-securities-class-action-lawsuit-against-innate-pharma-s-a-ipha\/"},"wordCount":352,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/important-dec-22-deadline-pawar-law-group-announces-a-securities-class-action-lawsuit-against-innate-pharma-s-a-ipha\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4NTM0MSMzODI1MjAyIzIwODMxNDk=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/important-dec-22-deadline-pawar-law-group-announces-a-securities-class-action-lawsuit-against-innate-pharma-s-a-ipha\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/important-dec-22-deadline-pawar-law-group-announces-a-securities-class-action-lawsuit-against-innate-pharma-s-a-ipha\/","name":"IMPORTANT DEC. 22 DEADLINE Pawar Law Group Announces a Securities Class Action Lawsuit Against Innate Pharma S.A.\u2013 IPHA - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/important-dec-22-deadline-pawar-law-group-announces-a-securities-class-action-lawsuit-against-innate-pharma-s-a-ipha\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/important-dec-22-deadline-pawar-law-group-announces-a-securities-class-action-lawsuit-against-innate-pharma-s-a-ipha\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4NTM0MSMzODI1MjAyIzIwODMxNDk=","datePublished":"2020-11-12T21:13:38+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/important-dec-22-deadline-pawar-law-group-announces-a-securities-class-action-lawsuit-against-innate-pharma-s-a-ipha\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/important-dec-22-deadline-pawar-law-group-announces-a-securities-class-action-lawsuit-against-innate-pharma-s-a-ipha\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/important-dec-22-deadline-pawar-law-group-announces-a-securities-class-action-lawsuit-against-innate-pharma-s-a-ipha\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4NTM0MSMzODI1MjAyIzIwODMxNDk=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4NTM0MSMzODI1MjAyIzIwODMxNDk="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/important-dec-22-deadline-pawar-law-group-announces-a-securities-class-action-lawsuit-against-innate-pharma-s-a-ipha\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"IMPORTANT DEC. 22 DEADLINE Pawar Law Group Announces a Securities Class Action Lawsuit Against Innate Pharma S.A.\u2013 IPHA"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/380339","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=380339"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/380339\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=380339"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=380339"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=380339"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}